U.S. Markets closed

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
41.26+1.76 (+4.46%)
At close: 4:00PM EDT

41.95 +0.69 (1.67%)
After hours: 4:53PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close39.50
Open39.48
Bid41.76 x 1300
Ask41.27 x 1200
Day's Range38.71 - 41.27
52 Week Range34.38 - 76.69
Volume417,910
Avg. Volume414,681
Market Cap1.834B
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-3.13
Earnings DateJul 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est74.00
  • UniQure (QURE) to Report Q3 Results: Wall Street Expects Earnings Growth
    Zacks

    UniQure (QURE) to Report Q3 Results: Wall Street Expects Earnings Growth

    UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

    LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two additional patient procedures have been completed in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease. The ongoing patient enrollment follows a meeting last month of the trial’s independent Data Safety Monitoring Board (DSMB) to review 90-day follow-up data from the first two patients. The DSMB observed no significant safety concerns to prevent further dosing.  The Phase I/II study is a double-blinded, randomized and controlled clinical trial being conducted in the United States. A total of four patients have been enrolled in the study thus far, including two patients treated with AMT-130 and two patients who received imitation surgery. “We are very pleased with the progress being made to advance this first-in-human AAV gene therapy for Huntington’s disease,” said Ricardo Dolmetsch, Ph.D., president of research and development at uniQure. “This is an important achievement that puts us on our original clinical development timeline, making up for the modest delay in the study earlier this year due to COVID-19. In accordance with the study protocol, patient enrollment is expected to continue after a DSMB meeting to review 90-day follow-up data on these two new patients and 6-month data on the first two patients. We expect that this DSMB review will take place early next year and that patient enrollment in the 10-patient first dose cohort will be completed by mid-2021.”The Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease will explore the safety, tolerability, and efficacy signals in 26 patients with early manifest Huntington’s disease randomized to treatment with AMT-130 or an imitation (sham) surgery across two dose cohorts. The multi-center trial consists of a blinded 12-month core study period followed by unblinded long-term follow-up for 5 years after administration of AMT-130. Patients will receive a single administration of AMT-130 through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen). Additional details are available on www.clinicaltrials.gov (NCT04120493).AMT-130 is uniQure’s first clinical program focusing on the central nervous system (CNS) incorporating its proprietary miQURE™ platform.About Huntington’s DiseaseHuntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, and behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Despite the clear etiology of Huntington’s disease, there are no currently approved therapies to delay the onset or to slow the disease’s progression.About uniQure uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.comuniQure Forward-Looking StatementsThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, whether patient enrollment will continue after a DSMB meeting to review follow-up data, whether the DSMB review will take place early next year, and whether patient enrollment in the first dose cohort will be completed by mid-2021. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with the impact of the ongoing COVID-19 pandemic on our Company and the wider economy and health care system, our clinical development activities, clinical results, collaboration arrangements, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure’s periodic securities filings, including its Annual Report on Form 10-K filed March 2, 2020 and Quarterly Report on Form 10-Q filed on July 30, 2020. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.uniQure Contacts:FOR INVESTORS:  FOR MEDIA:     Maria E. Cantor Direct: 339-970-7536 m.cantor@uniQure.comChiara Russo Direct: 617-306-9137 c.russo@uniQure.com Tom Malone Direct: 339-970-7558 t.malone@uniQure.com

  • GlobeNewswire

    uniQure to Participate in Multiple Upcoming Industry Conferences in October

    LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Matt Kapusta, chief executive officer at uniQure, Maria Cantor, chief communications officer, and Chiara Russo, associate director of investor relations and communications, will participate in the following upcoming conferences in October: * SVB Leerink CybeRx Series: Rare & Genetics, October 1, 2020 • Members of uniQure’s management team will participate in virtual one-on-one investor meetings in the afternoon on Thursday, October 1, 2020. * Jefferies Virtual Gene Therapy/Editing Summit, October 1 – 2, 2020 • A fireside chat with research analyst Suji Jeong, Ph.D. will take place on Friday, October 2, 2020 from 9:00 – 9:25 a.m. ET. The live webcast of the chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event. • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the morning on Friday, October 2, 2020. * Chardan Virtual 4th Annual Genetic Medicines Conference, October 5 – 6, 2020 • A fireside chat with research analyst Gbola Amusa will take place on Tuesday, October 6, 2020 from 1:00 – 1:25 p.m. ET. The live webcast of the chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event. • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the afternoon on Tuesday, October 6, 2020. About uniQure uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.comuniQure Contacts:     FOR INVESTORS: FOR MEDIA:     Maria E. CantorChiara RussoTom Malone Direct: 339-970-7536Direct: 617-306-9137Direct: 339-970-7558 m.cantor@uniQure.com c.russo@uniQure.com t.malone@uniQure.com